Corline Biomedical Q1: Initial take – Fairly in line with our expectations - Redeye
Bildkälla: Stockfoto

Corline Biomedical Q1: Initial take – Fairly in line with our expectations - Redeye

Redeye provides an initial take following the release of Corline’s Q1 2025 report. Overall, the report came in fairly in line with our expectations, and we highlight that more important quarters are ahead of us. We will provide a more in-depth research update, where we do not expect to make any dramatic changes to our forecasts.

Redeye provides an initial take following the release of Corline’s Q1 2025 report. Overall, the report came in fairly in line with our expectations, and we highlight that more important quarters are ahead of us. We will provide a more in-depth research update, where we do not expect to make any dramatic changes to our forecasts.
Börsvärldens nyhetsbrev